<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03396562</url>
  </required_header>
  <id_info>
    <org_study_id>17-0118</org_study_id>
    <nct_id>NCT03396562</nct_id>
  </id_info>
  <brief_title>The eXtroardinarY Babies Study: Natural History of Health and Neurodevelopment in Infants and Young Children With Sex Chromosome Trisomy</brief_title>
  <official_title>The eXtroardinarY Babies Study: Natural History of Health and Neurodevelopment in Infants and Young Children With Sex Chromosome Trisomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to research the natural history of neurodevelopment, health and early&#xD;
      hormonal function in infants with XXY/Klinefelter syndrome, XYY, XXX and other sex chromosome&#xD;
      variations in an effort to identify early predictors of developmental and health outcomes.&#xD;
      The Investigators will also evaluate different developmental screening tools in infants with&#xD;
      sex chromosome variations so the investigators can develop recommendations for pediatrician&#xD;
      caring for infants and young children with XXY/Klinefelter syndrome, XYY, XXX, and other sex&#xD;
      chromosome variations.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Sex Chromosome Trisomies (SCT) including Klinefelter (XXY), Trisomy X (XXX), and&#xD;
      XYY syndromes occur in 1 out of every 500 births and are associated with a broad phenotypic&#xD;
      spectrum including increased risk for developmental delays (DD), language/learning disorders,&#xD;
      and autism spectrum disorder (ASD). XXY is also associated with testicular failure, XXX&#xD;
      increases risk for ovarian failure, and disorders of insulin resistance and other medical&#xD;
      problems resulting in increased morbidity and mortality occur in all 3 SCTs. Historically,&#xD;
      less than 10% of SCT diagnoses occur in childhood, however the rate of newborns with SCT has&#xD;
      markedly increased with new noninvasive prenatal cell-free DNA (cfDNA) screening. SCT natural&#xD;
      history research is limited to studies from the 1970's, and the investigators have little&#xD;
      knowledge of early predictors of the wide heterogeneity in later outcomes. The high risk for&#xD;
      DD in SCT suggests that newborn screening may improve identification for DD and timely&#xD;
      initiation of interventions. However, it is not clear whether all SCT infants indeed require&#xD;
      intensive developmental assessments and therapies, or if primary care screenings are&#xD;
      sufficient to identify those in need. The surge in prenatal SCT diagnoses from cfDNA methods&#xD;
      provides an opportunity for longitudinal study of a cohort of infants to explore natural&#xD;
      history, and to improve care.&#xD;
&#xD;
      Aims: This study aims to: (1) describe and compare the natural history of neurodevelopment,&#xD;
      health and early gonadal function in infants with the 3 SCT conditions through a national&#xD;
      prospective eXtraordinarY Babies Study in partnership with the Newborn Screening&#xD;
      Translational Research Network (NBSTRN), (2) identify early predictors of poor&#xD;
      neurodevelopmental and cardiometabolic outcomes, and (3) evaluate the sensitivities of common&#xD;
      primary care developmental screening measures to detect DD and ASD in this high-risk&#xD;
      population to inform recommendations for an early neurodevelopmental care protocol.&#xD;
&#xD;
      Approach: Infants with a prenatal diagnosis of XXY, XYY, or XXX will be followed&#xD;
      prospectively every 6-12 months for 2-4 years at 2 eXtraordinarY Kids Clinic sites.&#xD;
      Demographics, health history, development, interventions, and social/family history will be&#xD;
      collected. Assessments will include: (1) measures of cognitive, language, social, motor, and&#xD;
      adaptive function, (2) physical exam, gonadal function labs, cardiometabolic measures, and&#xD;
      body composition, and (3) quality of life outcomes. Impact: Prospective study of the natural&#xD;
      history of prenatally diagnosed infants with SCT will allow investigation of important&#xD;
      questions to inform newborn screening considerations, such as the interplay between early&#xD;
      hormonal profiles and developmental outcomes. Results will be immediately relevant for&#xD;
      counseling and establishing evidence-based care guidelines for the rapidly increasing rate of&#xD;
      SCT diagnoses from cfDNA screening. Results will serve as the basis for ongoing longitudinal&#xD;
      studies of health and psychological outcomes of SCTs through the lifespan.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 29, 2017</start_date>
  <completion_date type="Anticipated">September 2022</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Longitudinal Descriptive Statistics of Cognitive Scores on the Bayley-III</measure>
    <time_frame>36 months</time_frame>
    <description>Cognitive skills will be assessed using the standardized Bayley Scales of Infant Development--3rd Edition (Bayley-3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal Descriptive Statistics of Motor Scores on the Bayley-III</measure>
    <time_frame>36 months</time_frame>
    <description>Motor development will be assessed using the standardized Bayley Scales of Infant Development--3rd Edition (Bayley-3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Longitudinal Descriptive Statistics of Language Scores on Bayley-III</measure>
    <time_frame>36 months</time_frame>
    <description>Language development will be assessed using the Bayley Scales of Infant Development--3rd Edition (Bayley-3)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Body Mass Index (BMI)</measure>
    <time_frame>36 months</time_frame>
    <description>BMI will be determined through measurement of length and weight at the research visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Z Score</measure>
    <time_frame>36 months</time_frame>
    <description>The z score will be calculated for age group at the research visit.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Composition (% body fat)</measure>
    <time_frame>3 year old visit</time_frame>
    <description>Body fat percentage will be measured using air Dual Energy X-Ray Absorptiometry (DEXA) at 3 year old visit.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Klinefelter Syndrome</condition>
  <condition>Trisomy X</condition>
  <condition>XYY Syndrome</condition>
  <condition>XXXY and XXXXY Syndrome</condition>
  <condition>Xxyy Syndrome</condition>
  <condition>Xyyy Syndrome</condition>
  <condition>Xxxx Syndrome</condition>
  <condition>Xxxxx Syndrome</condition>
  <condition>Xxxyy Syndrome</condition>
  <condition>Xxyyy Syndrome</condition>
  <condition>Xyyyy Syndrome</condition>
  <condition>Male With Sex Chromosome Mosaicism</condition>
  <arm_group>
    <arm_group_label>SCT Conditions</arm_group_label>
    <description>Sex Chromosome Trisomies Conditions including Klinefelter (XXY), Trisomy X (XXX), XXY Syndromes.&#xD;
Interventions: Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Assessments of Development and Growth</intervention_name>
    <description>Longitudinal observational assessments of development and growth at ages: 2 months, 6 months, 12 months, 18 months, 24 months, 36 months, 48 months, and 5 or 6 years.</description>
    <arm_group_label>SCT Conditions</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      A venous blood, urine and stool samples will be collected at each research visit, with the&#xD;
      exception of the 18 and 48 month visit.&#xD;
&#xD;
      Hormone levels (Follicle Stimulating Hormone, Luteinizing Hormone, Anti-Mullerian Hormone,&#xD;
      Inhibin B, Estradiol and Testosterone) will be analyzed. Some of the venous blood will be&#xD;
      collected for the purpose of banking serum, plasma, RNA and DNA for future studies. Urine and&#xD;
      stool samples will also be banked for future analysis.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Sex Chromosome Trisomies (SCT) including Klinefelter (XXY), Trisomy X (XXX), and XYY. Rare&#xD;
        sex tetrasomy and pentasomy conditions are also eligible.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Prenatal diagnosis of sex chromosome aneuploidy (by cfDNA, chorionic villi sampling,&#xD;
             and/or amniocentesis)&#xD;
&#xD;
          2. Postnatal confirmatory karyotype of XXY, XYY, XXX, XXYY, XYYY, XXXY, XXXX, XXXXX,&#xD;
             XXXXY, XXXYY, XXYYY, XYYYY (including any mosaicism with &lt;80% 46,XX or 46,XY cell&#xD;
             line)&#xD;
&#xD;
          3. English or Spanish speaking&#xD;
&#xD;
          4. Age 6 weeks to 12 months 30 days on enrollment&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Previous diagnosis of a different genetic or metabolic disorder with&#xD;
             neurodevelopmental or endocrine involvement&#xD;
&#xD;
          2. Prematurity less than 34 weeks gestational age&#xD;
&#xD;
          3. Complex congenital malformation not previously associated with sex chromosome&#xD;
             aneuploidy&#xD;
&#xD;
          4. History of significant neonatal complications (ie intraventricular hemorrhage,&#xD;
             meningitis, hypoxic-ischemic encephalopathy)&#xD;
&#xD;
          5. Known complex Central Nervous System (CNS) malformation identified by neuroimaging&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>13 Months</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole Tartaglia, MD MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole Tartaglia, MD, MS</last_name>
    <phone>(720) 777-8087</phone>
    <email>nicole.tartaglia@childrenscolorado.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Susan Howell, MS, CGC, MBA</last_name>
    <phone>720-777-8361</phone>
    <email>susan.howell@childrenscolorado.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Children's Hospital Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susan Howell, MS, CGC, MBA</last_name>
      <phone>720-777-8361</phone>
      <email>susan.howell@childrenscolorado.org</email>
    </contact>
    <contact_backup>
      <last_name>Mariah Brown</last_name>
      <phone>(720)777-6774</phone>
      <email>mariah.brown2@childrenscolorado.org</email>
    </contact_backup>
    <investigator>
      <last_name>Nicole Tartaglia, MD MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Shanlee Davis, MD MSCS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mariah Brown</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Tanea Tanda</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Susan Howell, MS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Lisa Cordeiro, MS, CSP</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rebecca Wilson, PsyD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jennifer Janusz, PsyD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laura Pyle, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nemours at Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judith Ross, MD</last_name>
      <phone>215-955-1648</phone>
      <email>jlross@nemours.org</email>
    </contact>
    <contact_backup>
      <last_name>Karen Kowal, PAC</last_name>
      <phone>215-9559008</phone>
      <email>karen.kowal@nemours.org</email>
    </contact_backup>
    <investigator>
      <last_name>Judith Ross, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Kowal, PAC</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mary Iampietro, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Amanda Alston</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>December 5, 2017</study_first_submitted>
  <study_first_submitted_qc>January 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 11, 2018</study_first_posted>
  <last_update_submitted>April 22, 2021</last_update_submitted>
  <last_update_submitted_qc>April 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>body composition</keyword>
  <keyword>klinefelter syndrome</keyword>
  <keyword>XXY</keyword>
  <keyword>Trisomy X</keyword>
  <keyword>XXX</keyword>
  <keyword>XYY</keyword>
  <keyword>XXYY</keyword>
  <keyword>XXXY</keyword>
  <keyword>XXXXY</keyword>
  <keyword>sex chromosome variation</keyword>
  <keyword>sex chromosome aneuploidy</keyword>
  <keyword>sex chromosome trisomy</keyword>
  <keyword>testosterone</keyword>
  <keyword>XYYY</keyword>
  <keyword>XXXX</keyword>
  <keyword>XXXXX</keyword>
  <keyword>XXXYY</keyword>
  <keyword>XXYYY</keyword>
  <keyword>XYYYY</keyword>
  <keyword>developmental delay</keyword>
  <keyword>speech development</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Klinefelter Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Trisomy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

